Featured Study Opportunities
The Crohn's & Colitis Foundation utilizes Featured Study Opportunities to collaborate with academic and industry researchers to help enroll patients with Crohn’s disease and ulcerative colitis into clinical studies. The list below highlights our partners' current research studies. Please note that these partners have paid to have their trials posted below. Some partners' studies listed may be recipients of partial or full funding from the Crohn's & Colitis Foundation. This support does not imply recommendation or favor of the Foundation, as the Crohn's & Colitis Foundation does not endorse any particular study.
For a comprehensive listing of all research studies currently recruiting, please click here.
(For e.g NY instead of New York)
Current Results: 84 entries
To investigate if circadian malalignment (unusual sleeping patterns), such as night shifts (sleeping during the day and being awake during the night time), worsens the inflammation of the gut.
The primary objective of this study is to evaluate the efficacy of tofacitinib based on remission in pediatric participants with moderately to severely active UC. The primary endpoint is remission by central read Mayo score following 44 weeks in the maintenance phase. Remission is defined by a Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0.
To evaluate the safety, tolerability, and localization and delivery function of the DDS2 Capsule using gamma scintigraphy in people with active UC in a fasted state. The DDS2 capsule features proprietary localization technology designed to enable precise study drug delivery at the site of disease in the GI tract. Safety and tolerability of the DDS2 capsule has previously been tested in healthy participants. In this study, the DDS2 capsule will deliver a saline solution containing a small amount of non-absorbed radioactive tracer upon entry into the colon of people with ulcerative colitis in a fasted state. Gamma scintigraphy will be used to assess the localization and delivery function of the capsule.
To evaluate the effect of efavaleukin alfa on induction of clinical remission.
Understand how diet influences inflammation, symptoms, and the biology of Crohn's disease
This is a clinical trial with healthy participants to:
• see how the study drug is tolerated, if there are significant side effects, and how people feel after taking it when given with a single dose of another medication (drug B)
• see if multiple doses of the study drug have an effect on the amount of drug B in your blood after a single dose
• measure how much of drug B is in your blood after you take a single dose
This is a clinical trial with healthy participants to:
• measure how a single oral dose of the study drug affects the body and certain types of blood cells and enzymes
• measure the amount of study drug in your blood 48 hours after a single dose
• see how a new drug under study is tolerated, if there are any significant side effects and how people feel after taking it
- To prevent relapse in patients with Ulcerative Colitis (UC) in remission after administering fecal microbiota transplant (FMT) capsules plus Standard-Of-Care (SOC) treatment compared to placebo plus SOC treatment for 12 weeks.
- To evaluate the safety of FMT capsules given orally for 12 weeks in patients with UC in remission.
We aim to increase patient knowledge on the impact of IBD on women’s lives.
To assess the safety of, as well as how a natural product derived from the Hops plant is broken down by the bacteria in the intestines of adults with Crohn’s disease.
The Featured Study Opportunities page is made possible in part by:
